1867

SmithKline Beecham Encouraging Rezulin Users to Switch to Avandia

SmithKline Beecham, maker of the glitazone Avandia, is working with doctors to help the transition of patients taking Rezulin to safer alternatives. SmithKline Beecham will be offering special services for type 2 diabetes patients to get more information about glitazones.

“Avandia is a clear choice for patients who need to transition from Rezulin to another glitazone, which will allow them to continue therapy with a safer and effective treatment alternative,” said David Krause, MD., vice president and director of clinical research development and medical affairs at SmithKline Beecham.

Over 700,000 patients have started taking Avandia in the United States and more than two million prescriptions have been written. It is approved for the treatment of type 2 diabetes in more than 26 countries.

Liver tests are recommended in all patients prior to initiation of therapy with Avandia and periodically thereafter. Avandia was generally well tolerated in clinical trials. Commonly reported adverse events were upper respiratory tract infections and headaches.

For more information, log on to SmithKline Beecham’s Web site at www.sb.com.

Leave a Reply

Your email address will not be published. Required fields are marked *


Time limit is exhausted. Please reload CAPTCHA.